Novartis Appoints New CEO

On Sept. 4, 2017, Novartis announced the appointment of Vasant Narasimhan, MD, as CEO of Novartis by its board of directors, effective Feb. 1, 2018. Dr. Narasimhan currently acts as the company’s global head of drug development, chief medical officer, and a member of the executive committee.

Dr. Narasimhan, who has been with the company since 2005, will replace Joseph Jimenez. Jimenez, who served in the position for 8 years, will be available for advising until his retirement on Aug. 31, 2018.

Source: Novartis